\n | \n(b)<\/td>\n | redeem 100 per cent of the Public Shares if the Company has
\nnot consummated a Business Combination by the Deadline Date, or such later time as the Members may approve in accordance with the Articles,
\neach holder of Public Shares who is not a Sponsor, a Founder, Officer or Director shall be provided with the opportunity to redeem their
\nPublic Shares upon the approval or effectiveness of any such amendment at a per-Share price, payable in cash, equal to the aggregate
\namount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released
\nto the Company to pay its taxes, divided by the number of then outstanding Public Shares. The Company\u2019s ability to provide such
\nredemption in this Article is subject to the Redemption Limitation.\u201d<\/td>\n<\/tr>\n<\/table>\n\u00a0<\/p>\n \u00a0<\/p>\n EXHIBIT 3.2<\/span><\/p>\n\u00a0<\/p>\n MINUTES OF AN EXTRAORDINARY
\nGENERAL MEETING OF SHAREHOLDERS OF VICKERS VANTAGE CORP. I<\/p>\n \u00a0<\/p>\n JUNE 30, 2022<\/p>\n \u00a0<\/p>\n An Extraordinary General Meeting
\n(the \u201cMeeting\u201d) of shareholders (\u201cthe Shareholders\u201d) of Vickers Vantage Corp. I the \u201cCompany\u201d),
\nwas held by telephonic conference on June 30, 2022 at 10:00 a.m. (Eastern Time). Each of the participants were able to speak and hear
\nthe other participants. In person attendance was available at The Nasdaq World Headquarters located at 151 W. 42nd St., 10FL Einstein
\nExecutive Conference Room, New York, NY 10036, USA.<\/p>\n \u00a0<\/p>\n In attendance were the following
\nmembers of the Company: Jeffrey Chi, Christopher Ho, Steve Myint and Rebekah Woo.<\/p>\n \u00a0<\/p>\n Also in attendance by telephone
\nconference were Joan Guilfoyle, outside counsel to the Company and Justin O\u2019Keefe, Senior Director of Morrow Soldali, a consultant
\nto the Company to act as Inspector of Election of this Meeting. Mr. Chi presided over the meeting as Chairman and Ms. Guilfoyle acted
\nas Secretary for the meeting. There was a quorum of Shareholders present at the Meeting.<\/p>\n \u00a0<\/p>\n The Chairman explained that
\nthere were two items on the agenda, and upon motion duly made and seconded, the Shareholders approved the following resolutions:<\/p>\n \u00a0<\/p>\n RESOLVED AS A SPECIAL RESOLUTION, that
\nthe Shareholders hereby authorize the Company to amend the Company\u2019s amended and restated memorandum and articles of association
\nto extend the date by which the Company has to consummate a business combination from July 11, 2022 to August 11, 2022 and allow the Company,
\nwithout another shareholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to 5 times
\nby an additional one month each time after the extended date, upon five days\u2019 advance notice prior to the applicable deadlines,
\nuntil January 11, 2023 (the \u201cAdditional Extension Date\u201d) or a total of up to 6 months after the original termination date,
\nunless the closing of the proposed Business Combination with Scilex Holding Company or any potential alternative initial business combination
\nshall have occurred (the full text of the special resolution is set out in Annex A).<\/p>\n \u00a0<\/p>\n \n\n| FOR<\/td>\n | \u00a0<\/td>\n | AGAINST<\/td>\n | \u00a0<\/td>\n | ABSTAIN<\/td>\n<\/tr>\n | \n| 13,254,634<\/td>\n | \u00a0<\/td>\n | 197<\/td>\n | \u00a0<\/td>\n | 15<\/td>\n<\/tr>\n<\/table>\n \u00a0<\/p>\n RESOLVED, that
\nthe Shareholders hereby authorize the Company to Adjourn the extraordinary Meeting of the Company to a later date or dates, if necessary,
\nto permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Meeting, there are insufficient
\nvotes to approve the Extension Proposal.<\/p>\n \u00a0<\/p>\n \n\n| FOR<\/td>\n | \u00a0<\/td>\n | AGAINST<\/td>\n | \u00a0<\/td>\n | ABSTAIN<\/td>\n<\/tr>\n | \n| 13,254,117<\/td>\n | \u00a0<\/td>\n | 729<\/td>\n | \u00a0<\/td>\n | 0<\/td>\n<\/tr>\n<\/table>\n \u00a0<\/p>\n There being no further business, the Meeting was adjourned.<\/p>\n \u00a0<\/p>\n \n\n| \u00a0<\/td>\n | Respectfully submitted,<\/span><\/td>\n<\/tr>\n\n| \u00a0<\/td>\n | \u00a0<\/td>\n<\/tr>\n | \n| \u00a0<\/td>\n | \/s\/ Joan Guilfoyle<\/td>\n<\/tr>\n | \n| \u00a0<\/td>\n | Joan Guilfoyle<\/span><\/td>\n<\/tr>\n\n| \u00a0<\/td>\n | Secretary <\/span><\/td>\n<\/tr>\n<\/table>\n \u00a0<\/p>\n \n\n| Approved:<\/span><\/td>\n | \u00a0<\/td>\n<\/tr>\n | \n| \u00a0<\/td>\n | \u00a0<\/td>\n<\/tr>\n | \n| \/s\/ Jeffrey Chi<\/td>\n | \u00a0<\/td>\n<\/tr>\n | \n| Jeffrey Chi <\/span><\/td>\n | \u00a0<\/td>\n<\/tr>\n | \n| Chief Executive Officer<\/span><\/td>\n | \u00a0<\/td>\n<\/tr>\n<\/table>\n \u00a0<\/p>\n \u00a0<\/p>\n ANNEX
\nA<\/span><\/p>\n\u00a0<\/p>\n EXTENSION
\nAMENDMENt<\/span><\/p>\n\u00a0<\/p>\n AMENDED AND RESTATED MEMORANDUM AND ARTICLES
OF ASSOCIATION
OF
VICKERS VANTAGE CORP.\u00a0I<\/p>\n \u00a0<\/p>\n \u201cRESOLVED, as a special resolution, that
\nthe Amended and Restated Memorandum and Articles of Association of the Company be amended by the deletion of the existing Articles\u00a048.7
\nand 48.8 in their entirety and the insertion of the following language in their place:<\/p>\n \u00a0<\/p>\n \n\n | \n48.7<\/td>\n | In the event that the Company does not consummate a Business
\nCombination by August\u00a011, 2022 (the \u201cExtension Date\u201d), or such later time as the Members may approve in accordance
\nwith the Articles, the Company shall:<\/td>\n<\/tr>\n<\/table>\n\u00a0<\/p>\n \n\n | \n(a)<\/td>\n | cease all operations except for the purpose of winding up;<\/td>\n<\/tr>\n<\/table>\n \u00a0<\/p>\n \n\n | \n(b)<\/td>\n | as promptly as reasonably possible but not more than ten\u00a0business
\ndays thereafter, redeem the Public Shares, at a per-Share price, payable in cash, equal to the aggregate amount then on deposit in the
\nTrust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company (less taxes
\npayable and up to US$100,000 of interest to pay dissolution expenses), divided by the number of then Public Shares in issue, which redemption
\nwill completely extinguish public Members\u2019 rights as Members (including the right to receive further liquidation distributions,
\nif any); and<\/td>\n<\/tr>\n<\/table>\n\u00a0<\/p>\n \n\n | \n(c)<\/td>\n | as promptly as reasonably possible following such redemption,
\nsubject to the approval of the Company\u2019s remaining Members and the Directors, liquidate and dissolve; subject in each case to its
\nobligations under Cayman Islands law to provide for claims of creditors and in all cases subject to the other requirements of Applicable
\nLaw.<\/td>\n<\/tr>\n<\/table>\n\u00a0<\/p>\n Notwithstanding this Article or any other
\nprovision of the Articles, without approval of the Members, the Directors may, at their option and upon five\u00a0days advance notice
\nprior to the applicable deadline, extend the period of time to consummate a Business Combination up to 5 times, each by an additional
\n1\u00a0month (for a total of up to 6\u00a0months to consummate a Business Combination) (the \u201cDeadline Date\u201d), unless
\nthe consummation and closing of a Business Combination shall have occurred.<\/p>\n \u00a0<\/p>\n The Company shall provide notice to the
\nMembers that an extension will be effected at least five\u00a0days prior to the applicable deadline.<\/p>\n \u00a0<\/p>\n \n\n | \n48.8<\/td>\n | In the event that any amendment is made to this Article that
\nwould affect the substance or timing of the Company\u2019s obligation to:<\/td>\n<\/tr>\n<\/table>\n\u00a0<\/p>\n \n\n | \n(a)<\/td>\n | provide for the redemption of the Public Shares in connection
\nwith a Business Combination; or<\/td>\n<\/tr>\n<\/table>\n\u00a0<\/p>\n \n\n | \n(b)<\/td>\n | redeem 100 per cent of the Public Shares if the Company has
\nnot consummated a Business Combination by the Deadline Date, or such later time as the Members may approve in accordance with the Articles,
\neach holder of Public Shares who is not a Sponsor, a Founder, Officer or Director shall be provided with the opportunity to redeem their
\nPublic Shares upon the approval or effectiveness of any such amendment at a per-Share price, payable in cash, equal to the aggregate
\namount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released
\nto the Company to pay its taxes, divided by the number of then outstanding Public Shares. The Company\u2019s ability to provide such
\nredemption in this Article is subject to the Redemption Limitation.\u201d<\/td>\n<\/tr>\n<\/table>\n\u00a0<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Exhibit 99.1<\/p>\n \u00a0<\/p>\n \n \u00a0<\/p>\n FOR IMMEDIATE RELEASE<\/p>\n \u00a0<\/p>\n Vickers Vantage Corp.
\nI Announces Shareholder Approval of Extension of Deadline to Complete Business Combination<\/p>\n \u00a0<\/p>\n July
\n5, 2022<\/span><\/p>\nNEW
\nYORK, NY, July 5, 2022 \/Newswire\/ —\u00a0Vickers Vantage Corp. I (NASDAQ: VCKAU, VCKA, VCKAW) (\u201cVickers\u201d), a
\nspecial purpose acquisition company, announced today that on June 30, 2022 its shareholders approved, at the extraordinary general
\nmeeting, (i) a proposal to amend Vickers\u2019s amended and restated memorandum and articles of association to (a) extend the date
\nby which it must consummate an initial business combination from July 11, 2022 (the \u201cOriginal Termination Date\u201d) to
\nAugust 11, 2022 (the \u201cExtended Date\u201d) and (b) allow Vickers, without another shareholder vote, to elect to extend the
\ndate to consummate a business combination on a monthly basis for up to five times by an additional one month each time after the
\nExtended Date, upon five days\u2019 advance notice prior to the applicable deadlines, until January 11, 2023 or a total of up to
\nsix months after the Original Termination Date (the \u201cExtension Proposal\u201d), unless the closing of the proposed business
\ncombination with Scilex Holding Company (\u201cScilex\u201d) or any potential alternative initial business combination shall have
\noccurred, and (ii) a proposal to adjourn the meeting to a later date, if necessary, to permit further solicitation and vote of
\nproxies in the event that there are insufficient votes for, or otherwise in connection with the approval of the Extension Proposal
\n(the \u201cAdjournment Proposal\u201d). The Extension Proposal and the Adjournment Proposal are described in detail in Vickers
\ndefinitive proxy statement dated June 7, 2022. <\/span>In connection with its solicitation of proxies in connection with the
\nExtension Proposal, the Company was required to permit its public shareholders to redeem their ordinary shares. Of the 13,800,000
\nordinary shares outstanding with redemption rights, the holders of 4,073,605 ordinary shares elected to redeem their shares at a per
\nshare redemption price of $10.25. As a result, approximately $41.8 million will be removed from the Company\u2019s trust account
\n(the \u201cTrust Account\u201d) to pay such holders and approximately $99.8 million will remain in the Trust Account. Following
\nthe redemptions, the Company will have 9,726,395 ordinary shares with redemption rights outstanding and the Registrant will deposit
\napproximately $323,888 (or approximately $0.0333 per ordinary share that remains outstanding) for each calendar month, or portion
\nthereof, that is needed by the Registrant to complete an initial business combination from July 11, 2022. For
\na summary of the voting results for each proposal please see Vickers\u2019s Current Report on Form 8-K filed on July 5, 2022 with
\nthe U.S. Securities and Exchange Commission (the \u201cSEC\u201d).<\/span><\/p>\nThe
\npurpose of the Extension Proposal is to permit sufficient time for Vickers to consummate its previously announced proposed business combination
\nwith Scilex, a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, \u201cSorrento\u201d)
\na commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic
\npain. For a summary of the material terms of the proposed transaction, please see Vickers\u2019s Current Report on Form 8-K filed on
\nMarch 18, 2022 with the SEC in connection with the announcement of the proposed business combination.<\/span><\/p>\nAbout Vickers Vantage Corp. I<\/p>\n \u00a0<\/p>\n Vickers Vantage Corp. I is a blank check company
\nformed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination
\nwith one or more businesses or entities. Vickers\u2019s securities are quoted on the NASDAQ stock exchange under the ticker symbols VCKAU,
\nVCKA and VCKAW. For more information, visit www.vickersvantage.com.<\/p>\n \u00a0<\/p>\n About Scilex Holding Company<\/p>\n \u00a0<\/p>\n Scilex Holding Company, a nearly 100% (or over 99.9%) majority-owned
\nsubsidiary of Sorrento Therapeutics, Inc., is an innovative revenue-generating company focused on acquiring, developing and commercialization
\nof non-opioid pain management products for treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global
\npain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products
\nto maximize quality of life. Highly positive results from the Phase III Pivotal Trial C.L.E.A.R Program for SEMDEXATM, its
\nnovel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex targets indications
\nwith high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with moderate to severe pain.\u00a0
\nScilex launched its first commercial product in October 2018 and is developing its late-stage pipeline, which includes a pivotal Phase
\n3 candidate and one Phase 2 and one Phase 1 candidate.\u00a0 Its commercial product, ZTlido\u00ae (lidocaine topical system) 1.8%, or ZTlido\u00ae,
\nis a prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with postherpetic
\nneuralgia, which is a form of post-shingles nerve pain.\u00a0 Scilex\u2019s three product candidates are SP-102 (injectable dexamethasone
\nsodium phosphate viscous gel product containing 10 mg dexamethasone), or SEMDEXA\u2122, a Phase 3, novel, viscous gel formulation of
\na widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, with FDA Fast Track status; SP-103
\n(lidocaine topical system) 5.4%, a Phase 2, triple-strength formulation of ZTlido\u00ae, for the treatment of low back pain; and SP-104,
\n4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia in multiple
\nPhase 1 programs expected to be initiated this year. For further information regarding the SP-102 Phase 3 efficacy trial, see NCT identifier
\nNCT03372161 \u2013\u00a0Corticosteroid Lumbar Epidural Analgesia for Radiculopathy \u2013 Full Text View \u2013 ClinicalTrials.gov.<\/p>\n \u00a0<\/p>\n Scilex Holding Company is headquartered in Palo Alto, California, with
\noperations in both Palo Alto and San Diego, California. For further information please visit www.scilexholding.com.<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n About Sorrento Therapeutics, Inc.<\/p>\n \u00a0<\/p>\n Sorrento is a clinical and commercial stage biopharmaceutical company
\ndeveloping new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento\u2019s multimodal,
\nmultipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully
\nhuman antibodies (\u201cG-MAB\u2122 library\u201d), immuno-cellular therapies (\u201cDAR-T\u2122\u201d), antibody-drug conjugates
\n(\u201cADCs\u201d), and oncolytic virus (\u201cSeprehvec\u2122\u201d). Sorrento is also developing potential antiviral therapies
\nand vaccines against coronaviruses, including Abivertinib, COVISHIELD\u2122 and COVI-MSC\u2122; and diagnostic test solutions, including
\nCOVIMARK\u2122.<\/p>\n \u00a0<\/p>\n Sorrento\u2019s commitment to life-enhancing therapies for patients
\nis also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin
\n(\u201cRTX\u201d), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA\u2122), a novel, viscous gel formulation
\nof a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido\u00ae
\n(lidocaine topical system) 1.8% for the treatment of postherpetic neuralgia (PHN). RTX has been cleared for a Phase II trial for intractable
\npain associated with cancer and a Phase II trial in osteoarthritis patients. Positive final results from the Phase III Pivotal Trial C.L.E.A.R.
\nProgram for SEMDEXA\u2122, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in
\nMarch 2022. ZTlido\u00ae was approved by the FDA on February 28, 2018.<\/p>\n \u00a0<\/p>\n For more information visit\u00a0www.sorrentotherapeutics.com<\/p>\n \u00a0<\/p>\n Important Information for Investors and
\nStockholders<\/p>\n \u00a0<\/p>\n This press release relates to a proposed
\ntransaction between Scilex and Vickers. This press release does not constitute an offer to sell or exchange, or the solicitation of an
\noffer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange
\nwould be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the transaction
\ndescribed herein, <\/span>Vickers has filed a Registration Statement on Form S-4 (the \u201cRegistration
\nStatement\u201d), which includes a document that serves as a prospectus and proxy statement of Vickers, referred to as the proxy statement\/prospectus.
\nAfter the Registration Statement is declared effective by the SEC, the proxy statement\/prospectus will be sent to all Vickers shareholders
\nas of a record date for the meeting of Vickers shareholders to be established for voting on the proposed business combination.\u00a0Vickers
\nwill also file other documents regarding the proposed transaction with the SEC. This press release does not contain all of the information
\nthat will be contained in the proxy statement\/prospectus or other documents filed or to be filed with the SEC. Investors and security
\nholders of Vickers are urged to read these materials (including any amendments or supplements thereto) and any other relevant documents
\nin connection with the transaction that Vickers files with the SEC when, and if, they become available because they will contain important
\ninformation about Vickers, Scilex and the proposed transaction.\u00a0 Investors and security holders will be able to obtain free copies
\nof the Registration Statement, the proxy statement\/prospectus and all other relevant documents filed or that will be filed with the SEC
\nby Vickers through the website maintained by the SEC at www.sec.gov.<\/p>\n\u00a0<\/p>\n Participants in the Solicitation<\/p>\n \u00a0<\/p>\n Vickers and its directors and executive
\nofficers may be deemed participants in the solicitation of proxies from Vickers\u2019s shareholders in connection with the transaction.
\nA list of the names of such directors and executive officers and information regarding their interests in the proposed business combination
\nwill be contained in the proxy statement\/prospectus when available. You may obtain free copies of these documents as described in the
\npreceding paragraph.<\/p>\n \u00a0<\/p>\n Scilex and its directors
\nand executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of Vickers in connection
\nwith the proposed transaction. Information about Scilex\u2019s directors and executive officers and information regarding their interests
\nin the proposed transaction will be included in the proxy statement\/prospectus for the proposed transaction.<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Non-Solicitation<\/p>\n This
\npress release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect
\nof the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Vickers,
\nthe combined company or Scilex, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer,
\nsolicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
\nNo offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.<\/span><\/p>\nForward-Looking Statements<\/p>\n \u00a0<\/p>\n This press release contains statements that constitute
\n\u201cforward-looking statements\u201d. Forward-looking statements are subject to numerous conditions, many of which are beyond the control
\nof Vickers, including those set forth in the Risk Factors section of Vickers\u2019s annual report on Form 10-K for the year ended December
\n31, 2021, filed with the SEC. Copies are available on the SEC\u2019s website, www.sec.gov. Vickers undertakes no obligation to update these
\nstatements for revisions or changes after the date of this release, except as required by law.<\/p>\n \u00a0<\/p>\n Contacts:<\/p>\n \u00a0<\/p>\n For Vickers Vantage Corp. I<\/p>\n \u00a0<\/p>\n Jeffrey Chi
Chief Executive Officer
85 Broad Street, 16th Floor
New York, NY 10004
Phone: (646) 974-8301
Email: [email\u00a0protected]<\/p>\n \u00a0<\/p>\n Website: www.vickersvantage.com<\/p>\n \u00a0<\/p>\n For Scilex Holding Company<\/p>\n \u00a0<\/p>\n Jaisim Shah
Chief Executive Officer
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310<\/p>\n Email: [email\u00a0protected]<\/p>\n \u00a0<\/p>\n Website: www.sorrentotherapeutics.com and www.scilexholding.com<\/p>\n \u00a0<\/p>\n Investors and Media Contact:<\/p>\n \u00a0<\/p>\n Contact:<\/p>\n \u00a0<\/p>\n Brian Cooley<\/p>\n Email: [email\u00a0protected]<\/p>\n Website: www.sorrentotherapeutics.com
\u00a0<\/p>\n Investors and Media Contact: Nicolette Ten, Senior Account Executive, SPRG
Email: [email\u00a0protected]<\/p>\n \u00a0<\/p>\n # # #<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n 3<\/p>\n \u00a0<\/p>\n","protected":false},"excerpt":{"rendered":" News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. \u00a0 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 \u00a0 FORM 8-K \u00a0 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 \u00a0 Date of Report (Date […]<\/p>\n","protected":false},"author":1,"featured_media":2028,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18],"tags":[19],"class_list":{"0":"post-2027","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ciatica","8":"tag-ciatica"},"_links":{"self":[{"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/posts\/2027","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/comments?post=2027"}],"version-history":[{"count":1,"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/posts\/2027\/revisions"}],"predecessor-version":[{"id":2029,"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/posts\/2027\/revisions\/2029"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/media\/2028"}],"wp:attachment":[{"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/media?parent=2027"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/categories?post=2027"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/tags?post=2027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} | | | | | | | | | | | | | |